XML 53 R12.htm IDEA: XBRL DOCUMENT
v3.20.1

MARKETABLE SECURITITES | 3 Months Ended
--- | ---
Mar. 31, 2020
Marketable Securities [Abstract] |
Marketable Securities Disclosure | MARKETABLE SECURITIES: Amortized cost and estimated fair market value of marketable securities classified as available-for-sale (excluding cash equivalents) at March 31, 2020, were as follows:
| Amortized Cost |  | Gross Unrealized |  | Estimated Fair Market Value
(In thousands) |  | Gains |  | Losses |
Investments due in 3 months or less: |  |  |  |  |  |  |
Commercial paper | $ | 14,869 |  |  | $ | — |  |  | $ | — |  |  | $ | 14,869 |
Corporate securities | 28,104 |  |  | 1 |  |  | (21 | ) |  | 28,084 |
Total | 42,973 |  |  | 1 |  |  | (21 | ) |  | 42,953 |
Investments due in 4-12 months: |  |  |  |  |  |  |
Corporate securities | 63,204 |  |  | 61 |  |  | (159 | ) |  | 63,106 |
Total | 63,204 |  |  | 61 |  |  | (159 | ) |  | 63,106 |
Investments due in 12 months or greater: |  |  |  |  |  |  |
Corporate securities | 126,375 |  |  | 145 |  |  | (396 | ) |  | 126,124 |
Total | 126,375 |  |  | 145 |  |  | (396 | ) |  | 126,124 |
Total marketable securities | $ | 232,552 |  |  | $ | 207 |  |  | $ | (576 | ) |  | $ | 232,183 |
Accrued interest receivable was $1.7 million at March 31, 2020 and was recorded within prepaid expenses and other current assets on the condensed consolidated balance sheet. Amortized cost and estimated fair market value of marketable securities classified as available-for-sale (excluding cash equivalents) at December 31, 2019, were as follows:
| Amortized Cost |  | Gross Unrealized |  | Estimated Fair Market Value
(In thousands) |  | Gains |  | Losses |
Investments due in 3 months or less: |  |  |  |  |  |  |
Corporate securities | $ | 15,934 |  |  | $ | 18 |  |  | $ | — |  |  | $ | 15,952 |
Total | 15,934 |  |  | 18 |  |  | — |  |  | 15,952 |
Investments due in 4-12 months: |  |  |  |  |  |  |
Corporate securities | 71,223 |  |  | 269 |  |  | — |  |  | 71,492 |
Total | 71,223 |  |  | 269 |  |  | — |  |  | 71,492 |
Investments due in 12 months or greater: |  |  |  |  |  |  |
Corporate securities | 144,658 |  |  | 302 |  |  | — |  |  | 144,954 |
Total | 144,658 |  |  | 302 |  |  | (6 | ) |  | 144,954 |
Total marketable securities | $ | 231,815 |  |  | $ | 589 |  |  | $ | (6 | ) |  | $ | 232,398 |
Accrued interest receivable was $1.3 million at December 31, 2019 and was recorded within prepaid expenses and other current assets on the condensed consolidated balance sheet. The following table summarizes marketable securities classified as available-for-sale (excluding cash equivalents) in a continuous unrealized loss position for which an allowance for credit losses has not been recorded at March 31, 2020 and December 31, 2019:
| Less Than 12 Months |  | 12 Months or Longer |  | Total
(In thousands) | Estimated Fair Market Value |  | Gross Unrealized Losses |  | Estimated Fair Market Value |  | Gross Unrealized Losses |  | Estimated Fair Market Value |  | Gross Unrealized Losses
March 31, 2020 |  |  |  |  |  |  |  |  |  |  |
Corporate securities | $ | 138,527 |  |  | $ | (576 | ) |  | $ | — |  |  | $ | — |  |  | $ | 138,527 |  |  | $ | (576 | )
Total marketable securities | $ | 138,527 |  |  | $ | (576 | ) |  | $ | — |  |  | $ | — |  |  | $ | 138,527 |  |  | $ | (576 | )
December 31, 2019 |  |  |  |  |  |  |  |  |  |  |
Corporate securities | $ | 13,069 |  |  | $ | (6 | ) |  | $ | — |  |  | $ | — |  |  | $ | 13,069 |  |  | $ | (6 | )
Total marketable securities | $ | 13,069 |  |  | $ | (6 | ) |  | $ | — |  |  | $ | — |  |  | $ | 13,069 |  |  | $ | (6 | )
In the three months ended March 31, 2020, no unrealized losses on marketable securities were recognized in income. The Company does not intend to sell and it is unlikely that it will be required to sell the securities prior to their anticipated recovery. The issuers are high quality (investment grade) and the decline in fair value is largely due to changes in interest rates and other market conditions. Additionally, the issuers continue to make timely interest payments on the marketable securities with the fair value expected to recover as they reach maturity.

X
- Definition The entire disclosure for investments in certain debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -URI http://asc.fasb.org/subtopic&trid=2209399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -URI http://asc.fasb.org/subtopic&trid=2324412 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 320 -URI http://asc.fasb.org/subtopic&trid=2176304 + Details
Name: | us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_MarketableSecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration